This trial tests a gene therapy called SENS-501 for children aged 6 to 31 months who are severely or profoundly deaf due to mutations in the otoferlin gene. The therapy is injected directly into one inner ear to deliver a working copy of the gene. The goal is to restore natural h…
Phase: PHASE1, PHASE2 • Sponsor: Sensorion • Aim: ⭐️ CURE ⭐️
Last updated Jul 10, 2026 00:00 UTC